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Introduction 
Alzheimer’s Disease (AD) is the most common form of dementia, affecting 13% of 
Americans aged at least 65 years and 43% of Americans aged at least 85 years.  It is a major 
driver of long-term care costs in the U.S., and there is currently no cure or preventative treatment.  
AD is defined by the appearance of two hallmark lesions: extracellular plaques composed of the 
beta-amyloid peptide and intracellular neurofibrillary tangles (NFTs) composed of the 
microtubule-binding protein tau. The accumulation of these proteins in aggregated forms is 
believed to contribute to the pathogenesis of AD. However, the accumulation of NFTs better 
correlates with disease and symtom progression, and the  quantity and distribution of NFTs, not 
plaques, are used to definitvely diagnose AD post mortem. For these reasons, the biology of 
normal tau protein, and how it malfunctions in disease, is being investigated for clues to the 
mechanisms underlying AD pathogenesis.  Normal tau protein functions in monomeric form to 
stabilize microtubules and promote their assembly.  In AD, however, tau aggregates into long 
fibrils that eventually grow to fill the neuronal cytoplasm.  Candidate triggers for this 
conformational change include post translational modifications (PTMs).  Previous work 
identified phosphorylation of Ser and Thr residues as major physiological PTMs capable of 
triggering tau aggregation.  More recent work conducted in model systems has revealed that 
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PTMs of Lys residues can also serve to modulate tau aggregation propensity.  But to date, Lys 
modifications have not been demonstrated at single residue resolution in authentic human brain 
specimens. 
To test the hypothesis that tau is normally modified on Lys residues, tau was isolated 
from normal human brain (n = 4; all cases 55 yr old) and subjected to a “bottom up” proteomic 
characterization.  In this approach, purified human tau protein was digested with the proteolytic 
enzyme trypsin, and the resulting peptides characterized by mass spectroscopy methods.  The 
resulting structural characterization revealed methylation as a novel tau PTM on Lys residues.  
The modification clustered perdominantly in the C-terminal region of the tau molecule known to 
mediate pathological self association.  To characterize the effects of Lys methylation on tau 
function, purified recombinant tau was subjected to chemical methylation to generate a library of 
modified tau species that varied with respect to methylation stoichiometry.  The methylated 
samples were then tested for their ability to promote microtubule assembly (i.e., normal tau 
function), as well as their ability to aggregate (i.e., pathological malfunction). To test the effect 
of methylation on tau’s microtubule assembly promoting activity, methyl tau was incubated with 
tubulin and an absorbance reading was taken every two minutes over the course of an hour to 
monitor the formation of microtubules. This experiment revealed that at lower, physiological 
levels, methylation did not inhibit tau’s ability to promote microtubule assembly. In contrast, a 
transmission electron microscope study examining aggregate formation of methyl tau showed 
that even low, physiological levels of methylation were able to inhibit tau aggregation. To 
characterize the mechanism of inhibition, the effects of Lys methylation on tau aggregation 
propensity was examined as function of time and tau protein concentration. These studies 
revealed that methylation inhibited aggregation by increasing the amount of protein needed to 
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form aggregates. It did so by increasing tau’s dissociation rate from fibrils, and decreasing the 
fibril extension rate.  In addition, methylation slowed aggregation rate by depressing filament 
nucleation, the rate limiting step in tau filament formation.   
Together these data show that low-occupancy methylation is a normal human tau PTM 
that does not affect tau’s normal function, but that does depress tau aggregation propensity. The 
experimental findings point to methylation being a potential regulatory PTM of tau. We postulate 
that methylation may decrease in AD compared to normal brain, and that maintaining or 
increasing methylation of tau could be a therapeutic approach for slowing the rate and extent of 
neurofibrillary lesion formation in  AD.  
Results 
The  first part of our study focused on identifying PTM in normal human brain. Soluble 





Table 1.  Case Demographics. 
 aAA, African American; C, Caucasian. 
bPost-mortem interval. 
cOSU, The Ohio State University Buckeye Brain Bank; NICHD, NICHD Brain and 
Tissue Bank for Developmental Disorders. 
dASCVD, atherosclerotic cardiovascular disease; HASCVD, hypertensive 
arteriosclerotic cardiovascular disease; PTSS, Post Traumatic Stress Syndrome. 	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These samples displayed no pathological plaque and tangle formation. These samples 
were subjected to trypsinization and then LC- MS/MS.  The mass spectromtry data was 
investigated using SEQUEST and MASCOT softwares wo identify post translational 
modifications. The data revealed a number of previously identified phosphorylation sites, as well 
as novel mono- and di- methylation sites on Lys residues. The peptides investigated covered 
90% of the sequence of the longest tau isoform 2N4R (shown in Figure 1), as well as 90% of 
Ser/Thr residues and 77% of Lys resides. (Fig.1). The phosphorylation sites predominantly 
corresponded with previously known sites. However, methylation sites were novel, identifying 
methylation as a normal PTM in human brain. The methylation primarily occurred in the 
microtubule binding repeat region of tau, responsible for both normal tubulin assembly and 
pathological aggregation.. Due to the importance of this region, we further investigated what 
effects methylation may have on both normal tau function and pathological aggregation.  
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FIGURE 1. Summary of modification sites on human tau proteins identified by LC-MS/MS.  
A, Identified tryptic peptides in the context of the human 2N4R isoform (NCBI accession number NP_005901), where the 
dotted underline depicts projection domain segments n1 and n2, the solid underline identifies the MTBR (as defined by 
(69)), and PHF6/PHF6* mark the hexapeptide segments involved in filament nucleation.  Font color depicts sequence 
coverage: blue, identified only in tissue-derived tau, red, identified only in recombinant 2N4R tau containing near-
saturating levels of methylation (21.8 mol/mol), and purple, identified in both.  Phosphorylation (P) sites are marked by 
green circles (hollow circles, novel sites; solid circles, previously reported sites), whereas methylation sites are marked by 
orange (me1, monomethylation) and red (me2, dimethylation) symbols (squares for tissue tau, triangles for recombinant 
tau).  B, Tau methylation and phosphorylation site distribution map (2N4R tau), showing location of modification sites 
relative to projection domain segments n1 and n2 and MTBR repeats r1 – r4.  The length of each bar corresponds to the 
number of cases in which the modification was found. 	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First we explored tau’s ability to perform its normal function, microtubule assembly. 
Recombinant 2N4R human tau was reductively methylated in vitro to varying degrees to 
investigate the role of methylation on microtuble assembly. Methylation was performed by 
incubationg 2N4R tau with formaldehyde and sodium cyanoborohydride at room temperature at 
variable timed up to one hour. Methylation stoichimetry was determined by performigng the 
reductive methylation using C14 formaldehyde. Methylation time course was modeled as a 




appeyy −−=  (1) 
where kapp and ymax are the rate constant and maximum extent of methylation, respectively. The 
methylation stoichometries and time course are seen in Figure 2A. 
 To determine the effect of methylation on tau-promoted microtubule assembly, purified 
tubulin dimers were incubated at 37°C alone or with unmodified or reductively methylated tau, 
and the extent of tubulin polymerization measured spectrophotometrically.  When tau was 
methylated at low levels (6 mol/mol and 10 mol/mol ) tubulin polymerization was no different 
than the non methylated control (Fig 2BC).  However, higher levels of methylation (16 mol/mol 
and 22 mol/mol) inhibited tau’s ability to promote microtubule assembly (Fig 2BC).  Overall, the 
data shows that only very high levels of methylation inhibit tubulin polymerization, and that low 
levels do not change tau’s ability to perform its normal function.  
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Additionally, we investigated the effect of methylation on tau’s patholigical function of 
aggregation. Reductively methylated tau of varying stoichiometries was incubated with thiazine 
red aggregation inducer under physiological pH, reducing conditions, and ionic strength. These 
aggregated samples were observed using transmission electron microscopy (TEM). The non-
methylated tau sample displayed aggregates similar to authentic brain-derived tau (Figure 3A). 
However, low levels of methylation severely inhibited tau aggregation. Figure 3B shows that 
even at the lowest methylation stoichiometry, 6 mol/mol, aggregation propensity is inhibited 
greatly. Although the amount of aggregation was diminished, the morphology of the filaments 
that did form were the same amoung all the samples, methylated and unmodified. This reveals 
that methylated tau shared the same aggregation characteristics as unmodifiec tau, but has a 
lower propensity for aggregation.  
FIGURE 2.  Effect of methylation on tau function in vitro. Purified recombinant human 2N4R tau 
protein was subjected to reductive methylation, then assayed for methylation stoichiometry and tubulin 
assembly promoting activity, respectively.  A, Time course of methylation determined in the presence of 
[14C]formaldehyde (n = 3) B, Effect of methylated tau (prepared in unlabeled formaldeyde) on tubulin 
assembly (37ºC) as measured by absorbance (A340 nm). C, Each data point represents triplicate 
determination of A340 ± SD as a function of time. Only very high methylation stoichiometries (≥16 
mol/mol) significantly depressed extent of tubulin assembly relative to unmodified 2N4R tau 	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To extend our study, we investigated the mechanism through which methylation inhibits 
aggregation. We used the unmodified control, and the lowest methylated sample (6 mol/mol) 
since the 6 mol/mol sample still exhibited measurable aggregation. These samples were 
incubated with thiazine red inducer under the conditions described previously. The abscissa 
intercepts of tau concentration dependence plots revealed that the minimal concentration for 
aggregation of methylated tau (5.5 mol/mol methylation stoichiometry) increased nearly 3-fold 
relative to unmodified tau (Fig. 4AB).  These data indicate that Lys methylation depressed 
aggregation propensity in part by increasing the concentration of tau needed to support fibril 
formation.  
In nucleation-elongation reactions, such as the tau aggregation reaction the minimal 
concentration approximates Kcrit, which corresponds to the equilibrium dissociation constant for 
elongation, Ke.   
Kcrit = ke-/ke+  (2)  
FIGURE 3. Lys methylation decreases tau aggregation propensity Recombinant 2N4R 
tau (2 µM) containing zero (A), 5 (B), 10 (C), 16 (D), or 22 (E) mol/mol methylation 
stoichiometry was incubated (18 h at 37ºC) in the presence of Thiazine red inducer, then 
assayed for filament formation by electron microscopy 	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Kcrit therefore reflects contributions from both the dissociation (ke-) and association (ke+) rate 
constants for filament elongation.  As a result, changes in Kcrit may stem from changes in either 
filament stability (ke-), efficiency of monomer association with filament ends (ke+), or both. To 
differentiate among these possibilities, initial filament disaggregation rates were estimated for 
unmodified and methylated (5.5 mol/mol stoichiometry) tau by diluting preassembled filaments 
below the Kcrit and measuring filament length as a function of time.  Under these conditions, loss 
of total filament length was found to decay following first-order kinetics (Fig. 4C). Rate constant 
ke+ was then calculated from estimates of ke- and Kcrit using Eq. 2.  Tau methylation was found 
increased ke- nearly 2-fold and decreased ke+ ~1.5-fold (Fig. 4D), suggesting that methylation 
increased minimal concentration by both weakening filament stability and slowing the rate of 
elongation.  	  
 
FIGURE 4.  Lys methylation modulates tau filament extension rates. A, Unmodified (solid 
circle) or 6 mol/mol methylated tau (hollow circle) were incubated (18 h at 37°C) at varying 
bulk concentrations in the presence of 100 µM Thiazine red inducer, then assayed for filament 
formation by electron microscopy. Total filament lengths were then plotted against bulk protein 
concentration. B, Replot of data from panel A, where each bar represents the Kcrit ± propagated 
SEE  C, Filaments prepared from unmodified (solid circle) and 5 mol/mol methylated tau 
(hollow circle) as described above were diluted below Kcrit in assembly buffer, and the resultant 
disaggregation followed as a function of time by electron microscopy. D, Replot of data from 
panel C, where each bar represents the ratio of rate constants for filament extension (ke+) and 
dissociation (ke-) determined for 5 mol/mol methylated versus unmodified tau ± propagated 
SEE. A ratio of 1, corresponding to no difference in rate, is marked by the dashed line.  	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In a homogeneous nucleation dependent reaction, the rate limiting step involves formation of a 
thermodynamic nucleus, defined as the least stable species reversibly interconverting with 
monomer. After a nucleus is formed, elongation proceeds efficiently. Overall aggregation rate 
depends on nucleation rate as well as protein concentration and the rate of elongation (ke- and 
ke+).  To determine whether methylation affected nucleation rate, tau aggregation time course 
was quantified for both unmodified and methylated (5.5 mol/mol stoichiometry) tau at constant 
supersaturation in the presence of thiazine red inducer. Under these conditions, differences in 
reaction rate primarily reflect differences in rates of nucleation and protein concentration.  When 
quantified over 24 hours, both time series displayed lag, exponential growth, and equilibrium 
phases (Fig. 5A).  Reaction lag times, which vary inversely with nucleation rate, were then 
estimated by fitting data with a 3-parameter Gompertz growth function.  Under these conditions, 
methylated tau aggregated with a significantly longer lag time relative to unmodified tau (Fig. 
5B). These data show that Lys methylation slows the nucleation phase of the tau aggregation 
reaction.  Overall, multi-site Lys methylation at 5.5 mol/mol can depress tau aggregation at both 
the nucleation and elongation steps without affecting microtubule polymerizing activity. 
 
FIGURE 5. Lys methylation depresses tau 
filament nucleation rate.  A, Either unmodified 
(solid circle) or 5 mol/mol methylated tau (hollow 
circle) was incubated at constant supersaturation 
(i.e., 0.3 µM above Kcrit) in the presence of 
Thiazine red inducer, then assayed for filament 
formation as a function of time Values for lag 
time were estimated from these plots. B, Replot of 
lag times determined from data in panel A, where 
each bar represents the lag time ± propagated 
SEE.  	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Summary 
 Figure 6 summarizes the findings of the previous studies. As is shown in figure 6, tau 
normally binds, stabilizes, and promoted tubulin assembly. In AD, tau dissociated from the 
microtubules, and undergoes a conformational change that makes it aggregation competent. 
These aggregation competent proteins are able to form a nucleus and then further aggregate into 
fibrils chracteristic of AD.  Our data shows that tau is a normally methylated in human brain 
samples. Methylation at low stoichiometries does not inhibit tau’s normal function, but it does 
modulate aggregation propensity Methylation strongly inhibits firbrilization by decreasin 
nucleation rate, decreasing fibril extension rate, and increasing dissociation rate. This data 
suggests that methylation could be a potential therapeutic target for AD. Increasing or 
maintaining the levels of methylation of tau could prevent or slow fibril formation. Further 
studies are needed to examine the methylation status of AD patients, as well as to explore 
avenues through which methylation levels of tau are controlled.  
 
 
FIGURE	  6.	  The	  effect	  of	  methylation	  on	  tau	  aggregation	  pathway.	  	  
